- Home
- ATNF vs WINT Comparison
ATNF vs WINT Comparison
Compare ATNF & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- WINT
- Stock Information
- Founded
- ATNF 2016
- WINT 1992
- Country
- ATNF United States
- WINT United States
- Employees
- ATNF N/A
- WINT N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATNF Health Care
- WINT Health Care
- Exchange
- ATNF Nasdaq
- WINT Nasdaq
- Market Cap
- ATNF 1.8M
- WINT 1.8M
- IPO Year
- ATNF N/A
- WINT 1995
- Fundamental
- Price
- ATNF $4.97
- WINT $1.07
- Analyst Decision
- ATNF
- WINT Hold
- Analyst Count
- ATNF 0
- WINT 1
- Target Price
- ATNF N/A
- WINT $18.00
- AVG Volume (30 Days)
- ATNF 5.6M
- WINT 3.0M
- Earning Date
- ATNF 11-07-2024
- WINT 11-07-2024
- Dividend Yield
- ATNF N/A
- WINT N/A
- EPS Growth
- ATNF N/A
- WINT N/A
- EPS
- ATNF N/A
- WINT N/A
- Revenue
- ATNF N/A
- WINT N/A
- Revenue This Year
- ATNF N/A
- WINT N/A
- Revenue Next Year
- ATNF $54.15
- WINT N/A
- P/E Ratio
- ATNF N/A
- WINT N/A
- Revenue Growth
- ATNF N/A
- WINT N/A
- 52 Week Low
- ATNF $1.16
- WINT $0.66
- 52 Week High
- ATNF $17.75
- WINT $22.32
- Technical
- Relative Strength Index (RSI)
- ATNF 67.64
- WINT 32.57
- Support Level
- ATNF $3.77
- WINT $1.04
- Resistance Level
- ATNF $8.00
- WINT $0.76
- Average True Range (ATR)
- ATNF 1.33
- WINT 0.17
- MACD
- ATNF 0.44
- WINT 0.18
- Stochastic Oscillator
- ATNF 22.97
- WINT 37.27
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.